TFS Capital’s Cardiff Oncology CRDF Stock Holding History

TFS Capital’s Portfolio CRDF Stock Details CRDF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q1	–	Sell	-178	Closed	-$73K	–	1375
2013 Q4	$73K	Buy	+178	New	+$79.2K	﹤0.01%	1414

Other funds holding CRDF

Bridger Management New York $150M AUM 17.71% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

RPAM

Rhenman & Partners Asset Management Stockholm, Sweden $1.06B AUM 52.03% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

AGM

Alpine Global Management New York $615M AUM 34.28% 1-Year Est. Return

Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return

TFS Capital's CRDF Position: Q1 2014 in Review

TFS Capital sold out of Cardiff Oncology (CRDF) in Q1 2014, closing a stake of 178 shares — an estimated $73K sold.

TFS Capital first reported a position in CRDF in Q4 2013 and held it in 1 quarter. The position peaked at $73K in Q4 2013. 22 funds tracked by Wall St. Rank hold CRDF as of Q1 2014.

TFS Capital reported no remaining Cardiff Oncology position as of Q1 2014 after selling out during the quarter.
TFS Capital sold 178 Cardiff Oncology shares in Q1 2014, an estimated $73K.
TFS Capital first reported a position in Cardiff Oncology in Q4 2013 and held it in 1 quarter.
TFS Capital's Cardiff Oncology position peaked at $73K in Q4 2013.
22 funds tracked by Wall St. Rank held Cardiff Oncology as of Q1 2014.

Based on TFS Capital's 13F filing for Q1 2014, filed 5 May 2014.